Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 16 peer-reviewed journal articles Updated
Hepatology

The Path to Healing: Standard of Care and Treatment Steps

At a Glance

The standard of care for Budd-Chiari Syndrome (BCS) uses a stepwise approach. Treatment starts with lifelong blood thinners to prevent new clots. If medication isn't enough, doctors use minimally invasive procedures like stenting or a TIPS bypass, reserving liver transplantation as a last resort.

Treating Budd-Chiari Syndrome (BCS) has changed dramatically in recent years. Instead of moving immediately to major surgery, doctors now use a stepwise approach. This means starting with the least invasive treatments and only moving to more complex procedures if the liver doesn’t show signs of “decongestion” or healing [1][2].

Step 1: Medical Therapy (The Foundation)

The first goal of treatment is to stop new blood clots from forming and to manage the symptoms of liver congestion.

Anticoagulation (Blood Thinners)

This is the cornerstone of BCS care. You will likely be on blood thinners for life to prevent the blockage from getting worse [3].

  • Traditional Therapy: For years, the standard has been heparin (injections) followed by warfarin (pills). Warfarin requires regular blood tests to ensure your levels are correct, and demands a consistent diet (particularly regarding Vitamin K intake) [4].
  • DOACs: Newer pills called Direct Oral Anticoagulants (like Eliquis or Xarelto) are becoming more common because they do not require frequent blood testing. However, DOACs are generally not recommended (and often contraindicated) if your BCS was caused by Antiphospholipid Syndrome (APS), as they carry a higher risk of recurrent clotting for these specific patients [5][6].

Step 2: Recanalization (Opening the Veins)

If medicine alone isn’t enough, the next step is often to physically open the blocked vein. This is called recanalization [7].

  • Angioplasty: A doctor inserts a small balloon into the vein and inflates it to stretch the blockage open [8].
  • Stenting: Often, a small mesh tube called a stent is placed inside the vein to keep it from narrowing again. This is particularly effective for “short-segment” blockages where only a small part of the vein is narrowed [8][9].

Step 3: TIPS (The Internal Bypass)

If the veins are too blocked to be opened with a stent, the TIPS procedure (Transjugular Intrahepatic Portosystemic Shunt) has become the gold-standard “rescue” treatment [10][11].

What is a TIPS?
Think of it as a “detour” or “bypass” inside your liver. An interventional radiologist uses a needle and a stent to create a tunnel that connects the blood entering the liver directly to the blood leaving the liver [12]. This allows blood to flow freely again, immediately reducing the high pressure that causes pain and fluid buildup [13][14].

Important Consideration: Hepatic Encephalopathy
Because a TIPS creates a bypass, some of the blood leaving your liver does not get filtered. This means toxins can reach your brain, potentially causing confusion, memory issues, or altered mental states—a condition called hepatic encephalopathy (HE) [15]. If you undergo a TIPS, your family should be on the lookout for cognitive changes, which can usually be managed with specific medications.

TIPS has revolutionized BCS care by providing a highly effective way to save the liver without needing a transplant [10][16].

Step 4: Liver Transplantation (The Last Resort)

While TIPS and stenting work for the majority of patients, a liver transplant remains a vital option for specific cases [16]. It is generally reserved for:

  1. Fulminant BCS: Patients who experience very sudden, rapid liver failure [3].
  2. TIPS Failure: Patients whose liver function does not improve even after a successful TIPS procedure [16].

The good news is that because of the stepwise approach and the success of TIPS, the number of BCS patients needing a transplant has dropped significantly [10]. When a transplant is necessary, however, long-term survival rates for BCS patients are generally very favorable.

Return to the Budd-Chiari Syndrome Resource Guide.

Common questions in this guide

Why do doctors use a stepwise approach to treat Budd-Chiari Syndrome?
Doctors start with the least invasive treatments, like blood thinners, to stop new clots and reduce liver congestion. They only escalate to more complex procedures, like a TIPS or transplant, if the liver does not heal with medication alone.
Can I take DOACs instead of warfarin for BCS?
Direct Oral Anticoagulants (DOACs) are becoming more common because they don't require frequent blood testing like warfarin. However, they are generally not recommended if your blood clots are caused by Antiphospholipid Syndrome (APS) due to a higher risk of recurrent clotting.
What is the difference between stenting and a TIPS procedure?
Stenting opens up your existing blocked vein using a small mesh tube to keep it wide open. A TIPS procedure, on the other hand, creates a completely new tunnel or 'bypass' inside your liver to route blood around the blocked vessels and relieve pressure.
What is hepatic encephalopathy and why does a TIPS cause it?
Because a TIPS creates a bypass tunnel, some blood leaves the liver without being filtered. This allows natural toxins to reach the brain, which can cause confusion, memory issues, or altered mental states—a condition that can usually be managed with specific medications.
Will I definitely need a liver transplant for Budd-Chiari Syndrome?
Thanks to highly effective procedures like TIPS, fewer patients need a liver transplant today. However, it remains an important life-saving option for patients who experience rapid liver failure or if their liver function does not improve after a successful TIPS procedure.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Do I qualify for a stepwise approach, or do my symptoms suggest I should move directly to an endovascular intervention?
  2. 2.Is my blockage considered a 'short-segment' stenosis that might be fixed with angioplasty and stenting?
  3. 3.What are the risks and benefits of using a DOAC versus traditional warfarin for my specific situation?
  4. 4.Am I a candidate for DOACs based on my specific clotting profile and underlying conditions?
  5. 5.If I receive a TIPS, what is the plan for monitoring the shunt to ensure it remains open?
  6. 6.At what point would we need to discuss liver transplantation as a back-up option?
  7. 7.Do I need an endoscopy to check for varices?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (16)
  1. 1

    Venous thrombosis of the liver: current and emerging concepts in management.

    Naymagon L

    Translational research : the journal of laboratory and clinical medicine 2020; (225()):54-69 doi:10.1016/j.trsl.2020.04.012.

    PMID: 32407789
  2. 2

    Timing of Transjugular Intrahepatic Portosystemic Shunt for Budd-Chiari Syndrome: An Italian Hepatologist's Perspective.

    Mancuso A

    Journal of translational internal medicine 2017; (5(4)):194-199 doi:10.1515/jtim-2017-0033.

    PMID: 29340275
  3. 3

    A case of Budd-Chiari syndrome with acute venous thrombosis and liver failure: highlighting the importance of early intervention and anticoagulation therapy.

    Otoyama Y, Kimura M, Nishikawa K, et al.

    Clinical journal of gastroenterology 2025; (18(4)):689-694 doi:10.1007/s12328-025-02135-w.

    PMID: 40272714
  4. 4

    Direct Oral Anticoagulants in Budd-Chiari Syndrome.

    Thapa SB, Souza GR, Paravathaneni M, et al.

    European journal of haematology 2025; (114(3)):566-572 doi:10.1111/ejh.14363.

    PMID: 39688028
  5. 5

    Dabigatran as an oral anticoagulant in patients with Budd-Chiari syndrome post-percutaneous endovascular intervention.

    Sharma S, Kumar R, Rout G, et al.

    Journal of gastroenterology and hepatology 2020; (35(4)):654-662 doi:10.1111/jgh.14843.

    PMID: 31476024
  6. 6

    Efficacy and Safety of Direct Oral Anticoagulants in Budd-Chiari Syndrome After Percutaneous Recanalization.

    Wu C, Shen Y, Gao Z, et al.

    Hepatology research : the official journal of the Japan Society of Hepatology 2026; (56(2)):195-203 doi:10.1111/hepr.70057.

    PMID: 41100307
  7. 7

    Early Endovascular Intervention in Combination with Medical Therapy versus Medical Therapy Alone in the Initial Management of Patients with Primary Budd-Chiari Syndrome: A Randomized Controlled Trial.

    Biswas S, Swaroop S, Mehta S, et al.

    Journal of vascular and interventional radiology : JVIR 2026; (37(3)):107967 doi:10.1016/j.jvir.2025.107967.

    PMID: 41421590
  8. 8

    Percutaneous transluminal angioplasty for symptomatic hepatic vein-type Budd-Chiari syndrome: feasibility and long-term outcomes.

    Elkilany A, Alwarraky M, Denecke T, Geisel D

    Scientific reports 2022; (12(1)):14095 doi:10.1038/s41598-022-16818-8.

    PMID: 35982064
  9. 9

    Angioplasty with versus without routine stent placement for Budd-Chiari syndrome: a randomised controlled trial.

    Wang Q, Li K, He C, et al.

    The lancet. Gastroenterology & hepatology 2019; (4(9)):686-697 doi:10.1016/S2468-1253(19)30177-3.

    PMID: 31279647
  10. 10

    Long Term Survival of Patients Undergoing TIPS in Budd-Chiari Syndrome.

    Sonavane AD, Amarapurkar DN, Rathod KR, Punamiya SJ

    Journal of clinical and experimental hepatology 2019; (9(1)):56-61 doi:10.1016/j.jceh.2018.02.008.

    PMID: 30765940
  11. 11

    Hepatic amyloidosis leading to hepatic venular occlusive disease and Budd-Chiari syndrome: A case report.

    Li TT, Wu YF, Liu FQ, He FL

    World journal of clinical cases 2019; (7(20)):3282-3288 doi:10.12998/wjcc.v7.i20.3282.

    PMID: 31667180
  12. 12

    The Role of Transjugular Intrahepatic Portosystemic Shunt for the Management of Ascites in Patients with Decompensated Cirrhosis.

    Iannone G, Pompili E, De Venuto C, et al.

    Journal of clinical medicine 2024; (13(5)) doi:10.3390/jcm13051349.

    PMID: 38592162
  13. 13

    TEN-YEAR OUTCOMES OF TIPS FOR BUDD-CHIARI SYNDROME: SYSTEMATIC REVIEW AND META-ANALYSIS.

    Moreno MOA, Paz CLDSL, Dezan MGF, et al.

    Arquivos de gastroenterologia 2024; (61()):e23171 doi:10.1590/S0004-2803.24612023-171.

    PMID: 38896573
  14. 14

    Role of Transjugular Intrahepatic Portosystemic Shunt in the Management of Portal Hypertension: Review and Update of the Literature.

    Hung ML, Lee EW

    Clinics in liver disease 2019; (23(4)):737-754 doi:10.1016/j.cld.2019.07.004.

    PMID: 31563220
  15. 15

    Acute-on-Chronic Liver Failure in Budd-Chiari Syndrome: Profile and Predictors of Outcome.

    Shalimar , Sharma S, Gamanagatti SR, et al.

    Digestive diseases and sciences 2020; (65(9)):2719-2729 doi:10.1007/s10620-019-06005-7.

    PMID: 31897895
  16. 16

    Long-term outcomes of transjugular intrahepatic portosystemic shunt in Budd-Chiari syndrome: A multicenter study.

    Swaroop S, Janeela AM, Valsan A, et al.

    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2025; (57(10)):1958-1964 doi:10.1016/j.dld.2025.06.026.

    PMID: 40716963

This page explains standard treatments for Budd-Chiari Syndrome for educational purposes only. Always consult your hepatologist or care team to determine the safest and most effective treatment plan for your specific situation.

Get notified when new evidence is published on Budd-Chiari syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.